Search research articles
Contact Us
Filters
Showing results (321-330 of 383) with videos related to
Page
of 39
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Gerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Oncotarget
|
November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis
Mehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
Clinical Genitourinary Cancer
|
July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer
Nicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results
Michael J Morris, Arturo Molina, Eric J Small, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2017
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Wei Zhang, Bo Liu, Wenhui Wu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2021
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment
Ioulia Vardaki, Paul Corn, Emanuela Gentile, et al.
Cancer Medicine
|
January 20, 2025
Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract
Mohammad Jad Moussa, Georges C Tabet, Arlene O Siefker-Radtke, et al.
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Wassim Abida, Andrew W Hahn, Neal Shore, et al.
Page
of 39
Search research articles
Search
Showing results (321-330 of 383) with videos related to
Sort By:
Page
of 39
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate
Gerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Oncotarget
|
November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis
Mehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
Clinical Genitourinary Cancer
|
July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer
Nicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 28, 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results
Michael J Morris, Arturo Molina, Eric J Small, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 16, 2017
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Wei Zhang, Bo Liu, Wenhui Wu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2021
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment
Ioulia Vardaki, Paul Corn, Emanuela Gentile, et al.
Cancer Medicine
|
January 20, 2025
Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract
Mohammad Jad Moussa, Georges C Tabet, Arlene O Siefker-Radtke, et al.
The Lancet. Oncology
|
November 13, 2012
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
Christopher J Logothetis, Ethan Basch, Arturo Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 16, 2024
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide
Wassim Abida, Andrew W Hahn, Neal Shore, et al.
Page
of 39